Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Blast Crisis × carfilzomib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 67 Recurrence 20 Neoplasms, Plasma Cell 6 Neoplasms 4 Lymphoma 3 Small Cell Lung Carcinoma 2 Waldenstrom Macroglobulinemia 1 Renal Insufficiency 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Kidney Neoplasms 1 Kidney Failure, Chronic 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Bone Marrow Neoplasms 1 Blast Crisis 1

Interventions

nilotinib 4 Imatinib Mesylate 4 Dasatinib 4 troxacitabine 1 ponatinib 1 litronesib 1 exatecan 1 carfilzomib 1 bosutinib 1 blinatumomab 1 asciminib 1 TAK-901 1 STA 9090 1 Panobinostat 1 Homoharringtonine 1 Fentanyl 1 Dexamethasone 1 Decitabine 1 Calcium Dobesilate 1 2-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01204164 2016-05-06

TG02-101

Tragara Pharmaceuticals, Inc.

Phase 1 Completed

Blast Crisis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡